<DOC>
	<DOC>NCT00561951</DOC>
	<brief_summary>To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.</brief_summary>
	<brief_title>Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Adult OAB patients who present with OAB symptoms, including micturitions &gt;= 8 per day and urgency urinary incontinence &gt;= 1 per day. Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients. Patient has a known neurological disease influencing bladder function. Patient has a complication of lower urinary tract pathology potentially responsible for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic organ prolapse.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>